Are Angiotensin-converting enzyme inhibitors and beta-blockers ineffective in children with dilated cardiomyopathy and heart failure?

. Morrow DA, Scirica BM, Sabatine MS, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non–ST-segment elevation acute coronary syndromes: observations from the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-STElevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2010;55:1189–96. . Scirica BM, Morrow DA, Karwatowska-Prokopczuk E, et al. Ventricular arrhythmias following non-ST segment elevation ACS and the relationship with sudden cardiac death in the MERLIN-TIMI 36 trial (abstr). J Am Coll Cardiol 2009;53:A121. . Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLINTIMI 36) randomized controlled trial. Circulation 2007;116:1647–52. . McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135–42. . Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002;8:416–22.